Alnylam Pharmaceuticals Inc · Q2 2021 earnings

Briefing

Alnylam's commercial performance in Q2 2021 demonstrated steady growth across its three wholly owned marketed products, with significant progress in the TTR franchise, including NDA submission and acceptance for vutrisiran.

Alnylam Pharmaceuticals reported a strong second quarter in 2021, achieving combined net product revenues of $161 million for ONPATTRO, GIVLAARI, and OXLUMO. The company also increased its 2021 revenue guidance range to $640-$665 million.

• Achieved Second Quarter 2021 Combined Net Product Revenues of $161 Million for ONPATTRO®, GIVLAARI®, and OXLUMO®.
• Advanced Vutrisiran with New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (FDA) for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis (hATTR-PN).
• Completed Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy (ATTR-CM).
• Increased 2021 Guidance Range for Combined Net Product Revenues from $610-$660 Million to $640-$665 Million.

Headline financials

Revenue & EPS history

Alnylam increased its 2021 revenue guidance for combined net product revenues to between $640 million and $665 million and expects net revenues from collaborations and royalties to be between $150 million and $200 million. GAAP R&D and SG&A expenses are expected to be between $1,335 million and $1,455 million. Non-GAAP R&D and SG&A expenses are expected to be between $1,175 million and $1,275 million.